MP
Publicaties op Oncologisch.com
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Fase III IPSOS Study.
The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Ther...
Eerstelijns atezolizumab mono versus chemotherapie bij NSCLC: IMpower110 langetermijn